Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucagon Jun 17 | 2019Xeris Glucagon Ph3 Top-line Data vs. Novo's GlucaGenPurchase Blast
$599
Posted in: Insulin Delivery Jun 13 | 2019Connected Care: Biocorp Receives CE Mark for MallyaPurchase Blast
$599
Posted in: GLP-1RA Jun 11 | 2019Oral Sema Market-Shaping; Novo's ADA 2019 PIONEER PresentationPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 10 | 2019ADA 2019 Key Press Releases (June 9 and 10)Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Jun 10 | 2019Lilly REWIND and Tirzepatide Comments From ADA 2019 Investor CallPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery Jun 10 | 2019Novo ADA 2019 Investor Event HighlightsPurchase Blast$599
Posted in: GLP-1RA Jun 10 | 2019Thoughts on REWIND; GLP-1RA Dynamics to Remain the SamePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jun 10 | 2019Medtronic Calls Out Tandem and Dexcom; Medtronic ADA 2019 Investor EventPurchase Blast$599
Posted in: Bolus Insulin Jun 09 | 2019URLi ISRs Could Sting LLY; Ph3 Results MixedPurchase Blast$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, SGLT2i Jun 08 | 2019Novo Oral Sema Data, Tirzepatide Ph2 Analyses, New Medtronic Pivotal Studies; ADA 2019 Key Press Releases (June 8)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Jun 07 | 2019Tidepool Partners with Medtronic and Dexcom; ADA 2019 Key Press Releases (June 7)Purchase BlastFree
Posted in: Basal Insulin, Bolus Insulin, Glucagon, Glucose Monitoring, Insulin Delivery, Other Jun 06 | 2019New Sanofi CEO; Xeris delayed: SENS approval, InPen-Dexcom; Zeal-BB; vTv; AdociaAccess Free Blast$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jun 06 | 2019ADA ’19 Key Data and Partnership Press Releases (June 5)Purchase Blast
$599
Posted in: DPP-IVi, SGLT2i Jun 04 | 2019BI/Lilly Empa+Lina+MetXR Triple FDC Filing Accepted By FDAPurchase Blast$599
Posted in: GLP-1RA Jun 03 | 2019REWIND: FENIX Team Split – Matt’s Bold Prediction vs. Team ConsensusPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery May 30 | 2019FENIX Analysis: Devices Promotional Materials Post-AACE 2019Purchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
